Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01708603 · ClinicalTrials.gov registry record · Phase 3
P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis
A Phase 3 study, sponsored by Bausch Health Americas.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,831
- Enrollment target
NCT01708603: Clinical Trial Phase 3 study, sponsored by Bausch Health Americas.
NCT01708603 is a Phase 3 study that was terminated before completion, run by Bausch Health Americas. The registered enrollment target is 1,831 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (137% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01708603, a Phase 3 study, was terminated before completion, sponsored by Bausch Health Americas.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,831 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses
Primary Outcome
Measures the physician's impression of the disease at a single point, and a dynamic form in which the physician assesses the global improvement from baseline. Success is defined by a score of 0 or 1 (clear to almost clear).
Interventions
- DRUG placebo
- DRUG ustekinumab
- DRUG 210 mg brodalumab
- DRUG 140 mg brodalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,831 participants |
| Start Date | 2012-08 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Why NCT01708603 stopped before completion
NCT01708603 is an interventional study that assigns participants to a tested intervention. Its 1,831 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (137% higher).
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT01708603 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01708603 about?
NCT01708603 is a clinical study titled "P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis". The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses
What is the current status of trial NCT01708603?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,831 participants. The study started on 2012-08. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01708603?
The interventions under investigation include: placebo (DRUG), ustekinumab (DRUG), 210 mg brodalumab (DRUG), 140 mg brodalumab (DRUG).
Who is sponsoring clinical trial NCT01708603?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01708603's enrollment target sits among peer trials
1,831 117th of 2000 higher than 1,884 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07104240 · 1,836 participants · NA
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
- NCT06740630 · 1,840 participants · Phase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- NCT06465810 · 1,850 participants
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- NCT06580080 · 1,850 participants · NA
Evaluation of Are You Ready?
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia